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Abstract
Previously, we have reported that the human papillomavirus (HPV) type 16 E6 D25E is the most prevalent variant in
Korean women at high risk for cervical cancers. Several studies have identified an association between the
increased frequency of this variant and the elevated risk of cervical intraepithelial neoplasia and invasive cervical
carcinoma. To investigate whether the HPV-16 E6 D25E variant might influence cervical cancer progression, we
used an oligonucleotide microarray approach to identify transcriptionally altered gene expression patterns in
recombinant wild-type E6 or E6 D25E variant-expressing HPV-negative cancer cells. We found that 211 genes were
significantly up- or down-regulated (at least 1.5-fold, p < 0.05). We identified 14 genes, nine down-regulated and
five up-regulated upon E6 D25E expression, compared with wild-type E6 expression. These results further
emphasize the unique biological activity of the HPV-16 E6 D25E variant.
Findings
High-risk types of the human papillomavirus (HPV) are
causative agents in most cases of cervical carcinoma.
Much of the transforming ability of this virus can be
attributed to the activities of its E6 and E7 oncoproteins
[1]. The gene for E6 is one of the earliest expressed dur-
ing HPV infection and plays an important role in cellular
immortalization and transformation [2]. The best-known
activity of E6 is its ability to accelerate the degradation of
the p53 protein [3]. E6 also has multiple transformation
properties such as regulating transcriptional regulators
and cellular homeostasis, which are finely tuned by con-
trolling proliferation, differentiation and apoptosis [4].
Interestingly, the E6 gene can immortalize primary
human mammary epithelial cells in culture [2] and
induced malignancy in a transgenic mouse model [5].
HPV-16 is the most frequent type found in invasive
cervical carcinoma (ICC) as well as in cervical intrae-
pithelial neoplasia (CIN) in Asian women. Accumulated
epidemiological studies suggest that certain HPV-16 E6
variants could influence the persistence of the infection
[6]. Furthermore, one HPV-16 E6 variant harboring an
amino acid change at position 83 by substituting leucine
for valine (L83V) was reported in Swedish and Italian
populations [7,8], and another change at position 25 by
substituting aspartic acid for glutamic acid (D25E) was
reported in Japanese [9] and Chinese [10] populations:
these were associated with the progression of cervical
carcinoma. Our previous study showed that HPV-16 E6
D25E is the most prevalent variant in Korean women at
high risk for developing cervical cancers [11]. However,
no studies have addressed the molecular relationship
between the E6 D25E variant and cervical carcinogen-
esis. To identify alterations in the gene regulatory net-
work that might be associated with the presence of the
HPV-16 E6 D25E compared with wild-type E6 in cervi-
cal carcinogenesis, we performed microarray analyses in
HPV-negative cancer cell lines expressing recombinant
wild-type E6 or E6 D25E variant proteins.
The HPV-negative cervical cancer cell line C33A was
purchased from the American Type Culture Collection
(Rockville, MD, USA) and maintained in modified
Eagle’s medium supplemented with 10% fetal bovine
serum (Gibco BRL, Rockville, MD, USA), penicillin (100
U/ml) and streptomycin (100 μg/ml) at 37 °C in a humi-
dified incubator with 5% CO2.
The wild-type E6 and D25E variant genes were ampli-
fied from HPV-16-infected cervical swabs [10] and
inserted into a pLenti6.3/V5-TOPO lentiviral vector
(Invitrogen, Carlsbad, CA, USA) followed by sequence
analysis. C33A cells were infected with the recombinant
lentivirus and the cells with stably maintained E6 genes
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Invitrogen).
To confirm the expression of the E6 genes, we per-
formed reverse transcription polymerase chain reaction
(RT-PCR) and immunofluorescence. Total cellular
RNAs were isolated using RNeasy kits (QIAGEN, Hil-
den, Germany) and RT-PCR reactions were performed
with OneStep RT-PCR kits (QIAGEN) according to the
manufacturer’s instructions. Primers used for amplifying
the gene sequence for E6 were: forward 5"-
GCAATGTTTCAGGACCCACA-3” and reverse 5"-
ACAGCATATGGATTCCCATCTC-3”. Primers for the
GAPDH gene (as internal control) were: forward 5"-
CCACAGTCCATGCCATC-3” and reverse 5"-TCCAC-
CACCCTGTTGCTGT-3”. The temperature profile
comprising the RT round was 50 °C for 30 min. The
PCR rounds involved denaturing at 95 °C for 15 min
followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s,
72 °C for 30 s and one cycle at 72 °C for 10 min. For
the immunofluorescence, cells were seeded in six-well
plates, fixed at room temperature for 15 min with BD
Cytofix/Cytoperm (BD Biosciences, Franklin Lakes, NJ,
USA) after twenty-four hours and treated for 30 min
with Image-iT FX signal enhancer (Invitrogen). Follow-
ing blocking with 3% bovine serum albumin in phos-
phate-buffered saline for 10 min, cells were incubated
with the primary antibody overnight at 4°C and with the
secondary antibody for 1 h at room temperature. The
primary antibody was anti-E6 (sc-460, Santa Cruz Bio-
technology, Santa Cruz, CA, USA) and the secondary
antibody was Alexa Fluor 546-labeled mouse immuno-
globulin G (A11003, Molecular Probes, Eugene, OR,
USA) (both at 1:100 dilution). Confocal imaging was
performed using an LSM 510 META microscope (Carl
Zeiss Microimaging GmbH, Jena, Germany). Messenger
R N Ae x p r e s s i o nl e v e l sf o rt h es u r v i v i ng e n ew e r ea n a -
lyzed via quantitative real time reverse transcription
polymerase chain reaction (RT-PCR) using a Bio-Rad
iCycler system (Bio-Rad, Hercules, CA, USA). Total
RNA was reverse-transcribed into cDNA using an
Omniscript RT kit (Qiagen). Primer specificity was
tested by running a regular PCR for 40 cycles (95°C for
20 s and 60°C for 1 min), followed by agarose gel elec-
trophoresis. Real time RT-PCR was performed using a
SYBR supermix kit (Bio-Rad). Samples were subjected to
45 cycles of 95°C for 20 s and 60°C for 1 min. PCR effi-
ciency was determined by running serial dilutions of
template cDNA, and melting curve data were collected
to assure PCR specificity. Each cDNA sample was ana-
lyzed in triplicate, and the corresponding no-RT mRNA
sample was included as a negative control. A GAPDH
primer was included in every plate as an internal loading
control. The mRNA level of each sample for survivin
gene was normalized against that of GAPDH mRNA.
The relative mRNA level was determined as 2
[(Ct/Actin -
Ct/gene of interest)]. All data are presented as the mean ±
standard deviation (SD) of three separate experiments.
T h ef o l l o w i n gp r i m e r sw e r eu s e df o rt h eq u a n t i t a t i v e
real time RT-PCR of survivin and actin genes: survivin
forward primer 5"-GCAATGTTTCAGGACCCACA-3”
and reverse primer 5"-AGGAACAGCCGAGAT-
GACCT-3” and actin forward primer 5"-ATCTGGCAC-
CACACCTTCTA-3” and reverse primer 5"-
GGATAGCACAGCCTGGATAC-3”. For microarray
analysis, the synthesis of target cRNA probes and hybri-
dization were performed from control and test RNAs
using Agilent’s Low RNA Input Linear Amplification kit
(Agilent Technology, Santa Clara, CA, USA) according
to the manufacturer’si n s t r u c t i o n s .T h ea r r a y sw e r e
hybridized at 65°C for 17 h using an Agilent hybridiza-
tion oven. The hybridized microarrays were washed
according to the manufacturer’s washing protocol. The
hybridized images were scanned using Agilent’sD N A
microarray scanner and quantified with feature extrac-
tion software. All data normalization and selection of
changed genes were performed using GeneSpringGX 7.3
(Agilent Technology). Functional annotation of genes
was performed according to the Gene Ontology™ Con-
sortium (http://www.geneontology.org/index.shtml)
using GeneSpringGX 7.3. Gene classification was based
on searches in BioCarta (http://cgap.nci.nih.gov/Path-
ways/BioCarta_Pathways), GenMAPP (http://www.gen-
mapp.org/), DAVID (http://david.abcc.ncifcrf.gov/) and
Medline databases (http://www.ncbi.nlm.nih.gov/).
To investigate the role of individual viral oncoproteins
of HPV-16 wild-type E6 and the D25E variant on cervi-
cal cancer progression, we stably transduced the E6
expression vector into C33A cells. Cells expressing the
E6 protein were selected and maintained in medium
containing blasticidin. The expression levels of E6 in
C33A cells were detected by RT-PCR and immunofluor-
escence. As shown in Figure 1, the E6 mRNA and pro-
tein were detected in wild-type E6- or D25E variant-
expressing C33A cells. In both cell lines, the expression
of E6 proteins was observed at similar levels. We
assessed the activation status of E6 proteins in con-
structed cell lines based on the mRNA level of the
downstream-regulated survivin gene. HPV-16 E6
induces endogenous survivin transcription [12]. This
gene is a member of the gene family involved in inhibit-
ing apoptosis [12]. We observed that the expression of
survivin was up-regulated in E6 proteins expressing
C33A cells using real-time PCR (Figure 1C). This con-
firmed that the expressed E6 proteins were active func-
tionally in C33A cells.
The HPV-16 E6 oncoprotein controls cellular gene
expression in host cells during infection, and microarray
technology should provide a useful experimental strategy
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Page 2 of 6for identifying the cellular target genes. By analyzing a
genome-wide microarray, we observed significant tran-
scriptional changes in 211 genes of the wild-type E6 or
D25E protein-expressing cell lines compared with the
control cell line using a filter criterion of at least 1.5-
fold change with p < 0.05. There were 118 common
transcripts revealed in both cell lines, 79 transcripts that
were regulated by wild-type E6a n d1 4t r a n s c r i p t st h a t
were unique in the E6 D25E-expressing cells. These
results indicate that E6 might have different biological
activities between variants. A hierarchical clustering heat
map (Figure 2A) and stylized Venn diagram (Figure 2B)
depict the patterns of changes in gene expression levels
in each E6-expressing cell line. A detailed list of the
gene signatures is presented in the supplemental data
(Additional file 1). Functional annotation of the genes
was assessed using gene ontology-based biological prop-
erty analysis (DAVID; http://david.abcc.ncifcrf.gov/). The
known annotations for 211 genes were submitted for
level 2 biological process analyses (Figure 2C). The
major gene population (>60%) was categorized as being
involved in the regulation of biological and cellular
metabolic processes. In addition, a minor gene popula-
tion (<10%) was associated with interspecies interactions
between organisms.
We have reported that E6 D25E is the most prevalent
variant (68%) in Korean women at high risk for cervical
cancers [11]. Epidemiological studies have shown an asso-
ciation of variation in the E6 genomic sequence with the
progression of high-grade precursor lesions to invasive
tumors [9,10,13]. The distribution of HPV 16 sequence
variations in ICC was found to vary geographically [14,15].
The incidences of the variants in ICC from Japanese
women were as follows: D25E in 44% of women, L83V in
28%, and other variants in 16% [9]. In China, HPV 16
D25E variant was detected in 62% of the patients with cer-
vical cancer [10]. Additionally, HPV-16 E6 L83V is asso-
ciated with an increased risk of persistent infection and
cytological progression to CIN types 2 and 3 and to squa-
mous cell carcinoma in European populations [6,7,15]. In
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Figure 1 Confirmation of HPV-16 E6 oncogenes expression and effects on the transcription of endogenous survivin gene in C33A cell
lines with e6 oncogenes. A. Quantification of mRNA of wild-type E6 and E6 D25E in C33A cells by RT-PCR performed using OneStep RT-PCR
kits. GAPDH mRNA was measured as a loading control. B. Protein expression analysis of wild-type E6 or E6 D25E using confocal microscopy.
Caski cells were used as a positive control. C. Quantative real-time PCR specific for survivin gene.
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Page 3 of 6agreement with epidemiological studies showing a link
between the L83V variant and an increased risk of malig-
nant disease, functional studies have demonstrated that
the E6 L83V variant has biological advantages over E6
wild-type. One model of cervical tumor progression
induced by the E6 oncogene is activation of mitogen-acti-
vated protein kinase (MAPK) signaling via the oncogenic
protein Ras [16]. This effect is enhanced by the E6 L83V
variant, which activates the MAPK signaling through
Rap1, independent of Ras [16]. Zehbe et al. [17] evaluated
functions relevant to carcinogenesis for the E6 variants
L83V, R10/L83V and Q14H/H78Y/L83V as well as for the
prototype. K5 and K10, markers for cell differentiation,
were detected among the E6 prototype and raft cultures of
variants. The E6 variants but not the prototype expressed
K5 and K10 within the suprabasal compartment in all
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Figure 2 Transcriptome analysis revealing gene expression patterns by E6 oncoproteins. A. Hierarchical cluster analysis of the wild-type
E6 or E6 D25E viral oncogene expression microarrays. A cluster-based representation of altered genes in E6 wild-type or E6 D25E expressed
C33A with intensity provided for each cell line, normalized to the control (C33A cells not expressing E6). Genes that were up-regulated relative
to control are shown in red and those that were down-regulated are green. The expression levels of these genes were altered ≥1.5-fold or ≤0.6-
fold in E6-expressing cell lines compared with controls (p < 0.05). Gene symbols are shown for all in the right row. The hybridization was
conducted in duplicate and denoted with 1 and 2. B. A venn diagram showing the numbers of genes regulated by wild-type E6 or E6 D25E.
The numbers of up- or down-regulated genes that responded commonly or uniquely in response to the expression of each E6 protein are
shown in red or blue arrows, respectively. The complete list of 211 genes is shown in additional file 1 and the entire microarray data set has
been deposited in the Gene Ontology Consortium database (http://www.geneontology.org/index.shtml). C. Gene ontology-based analysis.
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Page 4 of 6keratinocytes at the same time. Replication of suprabasal
keratinocytes preserves coexpression of K5 and K10
because the premature migration of proliferating keratino-
cytes into the suprabasal compartment is a hallmark of
early squamous cell carcinogenesis [18]. This phenotype
indicates that E6 variants might be associated with pro-
moting carcinogenesis.
Until now, there have been no experimental data on
the impact of this single amino acid 25 change in proto-
type E6, the dominant variant in Asia region, on pro-
gression to invasive carcinomas. This study aimed at
identifying genes affected by the HPV-16 E6 D25E var-
iant in comparison with the wild-type E6 in the C33A
HPV-negative cervical cancer cell line using microar-
rays. A genomic approach using oligonucleotide micro-
arrays showed that 14 genes involved in interspecies
interactions between organisms (including the immune
system) and stress response were modulated by the E6
D25E oncogene at an mRNA level. Nine genes (ZMZ1,
RPL23, MAPK4, RPL31, RARS, LAMB3, HSPA14,
AIFM2, IFRD1) were down-regulated and five genes
(UBC, RPS9, HLA-A, -B, ROCK2) were up-regulated in
E6 D25E expressing cells. The specific functions of
these genes in cervical oncogenesis remain to be eluci-
dated. However, it is conceivable that genes such as
AIFM2, RPL23, and ROCK2 could influence disease pro-
gression and promote potential carcinogenicity. In the
present study, AIFM2 was reduced in E6 D25E onco-
protein expressing cell lines. It has been reported that
AIFM2 has a pro-apoptotic function and that its expres-
sion is down-regulated in cancer cell lines by compari-
son with normal cell lines [19]. Inhibition of apoptosis
is a mechanism of survival for virally or chemically
transformed malignant cells. It means that E6 D25E
might be involved to promote the survival of HPV-
infected cells in a manner that facilitates tumor
development.
We have also observed down-regulation of the RPL23
gene associated with cell cycle and apoptosis. RPL23
could stabilize p53, inhibiting its degradation and thus
resulting in substantial cell cycle arrest at the G1-S
checkpoint and/or apoptotic cell death in the cultured
gastric cancer cell lines MKN45 and AGS as evidence
for the antitumor activity [20]. From our data, reduced
RPL23 expression might affect DNA synthesis and apop-
tosis inhibition through the p53 pathway. This result
indicates that RPL23 might be directly or indirectly
related to oncogenesis by E6 D25E.
In this study, based on microarray analysis, we showed
that ROCK2 is up-regulated in E6 D25E expressing cell
lines. ROCK2 kinase plays a critical role in promoting cen-
trosome duplication and amplification [21]. In general,
centrosome amplification frequently occurs in various can-
cers, and is considered a major cause of chromosomal
instability. Overexpression of ROCK2 has also been linked
frequently to enhanced metastatic potential (increase in
migration and invasion of tumor cells) in various cancer
types [22,23]. This increased expression of ROCK2 is indi-
cative of a possible involvement of E6 D25E protein in the
malignant transformation of cervical cells.
Our data showed that the MAPK pathway-associated
genes MAPK-2, -3 and -4 were down-regulated in con-
trast to L83V and the expression levels of immune
response-related human histocompatibility leukocyte
antigen (HLA) genes HLA-A and HLA-B were elevated
in E6 D25E-expressing cells. Down-regulation of HLA
Class I genes (HLA-A, -B and -C) is associated with cer-
vical neoplastic lesions and HLA polymorphisms might
influence oncogenicity by HPV infection, most likely
through an immunological mechanism [24]. These find-
ings are in the conflict with the epidemical data [6,10]
for oncogenic role of variant but it is still unclear
whether HPV variant D25E have distinct oncogenical
properties via HLA or MAPK regulation.
This is the first study to identify functional differences
in the naturally occurring HPV-16 E6 D25E variant in
C33A cell lines and provides a basis for future mechan-
istic studies. We observed that the HPV-16 E6 D25E-
expressing C33A cells modulated several functional
genes compared with wild-type E6-expressing cells. This
result contributes new and useful information to sup-
port the epidemiological data showing that there is
more frequent detection of the D25E variant in patients
with cervical cancer, and that several genes such as
AIFM2, RPL23,a n dROCK2 might be involved in cervi-
cal tumorigenicity via E6 D25E. Our findings suggest
that E6 D25E might have a unique oncogenic role in
cancerous transformation but further studies are needed
to define the molecular mechanisms and carcinogenic
potential of the HPV-16 D25E variant.
Additional material
Additional file 1: The list of genes differentially changed in C33A
cells expressing E6 proteins. The list shows genes that were
significantly altered (≥1.5-fold or ≤0.6-fold, p < 0.05) in E6-expressing cell
lines compared with controls. The fold change of these genes is mean of
2 independent experiments.
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